157 related articles for article (PubMed ID: 38035709)
1. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.
Dobilas A; Chen Y; Brueffer C; Leandersson P; Saal LH; Borgfeldt C
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):763-770. PubMed ID: 38035709
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
3. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
Han MR; Lee SH; Park JY; Hong H; Ho JY; Hur SY; Choi YJ
Cancer Res Treat; 2020 Jul; 52(3):779-788. PubMed ID: 32106643
[TBL] [Abstract][Full Text] [Related]
7. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
8. Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.
Chao A; Chen SJ; Chen HC; Tan KT; Hsiao W; Jung SM; Yang LY; Huang KG; Chou HH; Huang HJ; Chang TC; Chao AS; Lee YH; Wu RC; Lai CH
Biomed J; 2023 Oct; 46(5):100563. PubMed ID: 36208860
[TBL] [Abstract][Full Text] [Related]
9. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
10. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
11. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Hou JY; Chapman JS; Kalashnikova E; Pierson W; Smith-McCune K; Pineda G; Vattakalam RM; Ross A; Mills M; Suarez CJ; Davis T; Edwards R; Boisen M; Sawyer S; Wu HT; Dashner S; Aushev VN; George GV; Malhotra M; Zimmermann B; Sethi H; ElNaggar AC; Aleshin A; Ford JM
Gynecol Oncol; 2022 Nov; 167(2):334-341. PubMed ID: 36117009
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
16. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
17. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
19. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
[TBL] [Abstract][Full Text] [Related]
20. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
